CompletedPhase 1NCT00990717

Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Armand Keating, MD, PA-C
Princess Margaret Hospital, Canada
Intervention
NK-92 cells(biological)
Enrollment
8 enrolled
Eligibility
18 years · All sexes
Timeline
20052012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00990717 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials